Clinical Trials Directory

Trials / Conditions / Epidermolysis Bullosa Dystrophica

Epidermolysis Bullosa Dystrophica

19 registered clinical trials studyying Epidermolysis Bullosa Dystrophica — 3 currently recruiting.

StatusTrialSponsorPhase
RecruitingA Natural History Study of Corneal Abrasions in Patients With Dystrophic Epidermolysis Bullosa (DEB)
NCT06563414
Krystal Biotech, Inc.—
RecruitingStudy of the Blood and Skin Immunological Profile of Patients With Recessive Dystrophic Epidermolysis Bullosa:
NCT06177353
Assistance Publique - Hôpitaux de Paris—
UnknownCACIPLIQ20 in Wound Healing in Subjects With Epidermolysis Bullosa
NCT06007235
Organ, Tissue, Regeneration, Repair and ReplacementN/A
Active Not RecruitingArtificial Intelligence Patient App for RDEB SCCs
NCT05843994
Northwestern University—
UnknownGrowth Hormone in EB
NCT05390073
Cairo University—
CompletedINM-755 (Cannabinol) Cream for Treatment of Epidermolysis Bullosa
NCT04908215
InMed Pharmaceuticals Inc.Phase 2
CompletedRigosertib for RDEB-SCC
NCT03786237
Prof. Johann BauerPhase 1 / Phase 2
UnknownThe State of Sexual Development in Children With Inherited Epidermolysis Bullosa
NCT05033574
National Medical Research Center for Children's Health, Russian Federation—
WithdrawnA Pilot Study to Explore the Role of Gut Flora in Epidermolysis Bullosa
NCT04213703
ProgenaBiome—
Active Not RecruitingSelf-Assembled Skin Substitute for the Treatment of Epidermolysis Bullosa
NCT04171661
CHU de Quebec-Universite LavalEARLY_Phase 1
UnknownComputational Drug Repurposing for All EBS Cases
NCT03269474
Joyce Teng—
CompletedProof of Concept Study for a Dressing Glove
NCT03241628
Guy's and St Thomas' NHS Foundation Trust—
CompletedTreatment of Chronic and Non-Chronic Wounds in Patients With Recessive Dystrophic Epidermolysis Bullosa Using
NCT01716169
Stanford UniversityN/A
CompletedGene Transfer for Recessive Dystrophic Epidermolysis Bullosa
NCT01263379
Abeona Therapeutics, IncPhase 1 / Phase 2
CompletedTreatment of Epidermolysis Bullosa Dystrophica by Polyphenon E (Epigallocatechin 3 Gallate)
NCT00951964
Centre Hospitalier Universitaire de NicePhase 2
RecruitingCharacteristics of Patients With Recessive Dystrophic Epidermolysis Bullosa
NCT01019148
Stanford University—
CompletedCharacteristics of Adult Patients With Recessive Dystrophic Epidermolysis Bullosa
NCT00904163
Stanford University—
TerminatedSafety and Efficacy of Apligraf in Nonhealing Wounds of Subjects With Junctional or Dystrophic Epidermolysis B
NCT00587223
OrganogenesisPhase 3
TerminatedRecessive Dystrophic Epidermolysis Bullosa Screening for Possible Gene Transfer
NCT00533572
Stanford University—